Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rosaria D'Apollo"'
Publikováno v:
European Heart Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acdfb26759c1f3e12b83f8406fea8907
https://doi.org/10.1093/eurheartj/ehad302
https://doi.org/10.1093/eurheartj/ehad302
Autor:
Samantha Pozzi, Patrizia Pizzichini, Alessia Bari, Luigi Marcheselli, Daniela Prosperi, Maria Christina Cox, Raffaella Marcheselli, A. Casolo, Antonella Franceschetto, Rosaria D'Apollo, Ilana Levy, Tamar Tadmor, Lucia Massi, Napoleone Prandini, Stefano Sacchi
It is well established that some patients with diffuse large B-cell lymphoma (DLBCL) and the negative end of treatment PET-CT (EOT-PET-CT) will relapse, while a proportion with positive uptake can still obtain long-term EFS. We reviewed data of 200 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54a133a200c9da4be6a777f94db2f0e5
https://hdl.handle.net/11380/1200856
https://hdl.handle.net/11380/1200856
Autor:
Cosimo, Durante, Teresa, Montesano, Massimo, Torlontano, Marco, Attard, Fabio, Monzani, Salvatore, Tumino, Giuseppe, Costante, Domenico, Meringolo, Rocco, Bruno, Fabiana, Trulli, Michela, Massa, Adele, Maniglia, Rosaria, D'Apollo, Laura, Giacomelli, Giuseppe, Ronga, Sebastiano, Filetti, Leonardo, D'Aloiso
The current use of life-long follow-up in patients with papillary thyroid cancer (PTC) is based largely on the study of individuals diagnosed and treated in the latter half of the 20th century when recurrence rates were approximately 20% and relapses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049f1dea908a25cf505a69a2c155d4aa
http://hdl.handle.net/11573/510065
http://hdl.handle.net/11573/510065
Autor:
Samantha Pozzi, Rosaria D'Apollo, Virginia Rossetti, Luigi Marcheselli, Alessia Bari, Napoleone Prandini, Antonella Franceschetto, Monica Barbolini, Stefano Sacchi, Raffaella Marcheselli
Publikováno v:
ResearcherID
Background Despite the majority of DLBCL patients achieve long-term disease-free survival with standard chemo-immunotherapy, almost 30% of patients relapse or have refractory disease (1).Thus, there is an unmet need to identify patients with resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0fec8118a3b7d65732f94061b4068f
https://doi.org/10.1182/blood.v128.22.5406.5406
https://doi.org/10.1182/blood.v128.22.5406.5406
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.